Shares of Xtant Medical Holdings Inc (NASDAQ:XTNT) have been given an average broker rating score of 1.00 (Strong Buy) from the three brokers that provide coverage for the company, Zacks Investment Research reports. Three investment analysts have rated the stock with a strong buy recommendation.
Brokers have set a one year consensus price objective of $5.33 for the company and are anticipating that the company will post ($0.31) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Xtant Medical Holdings an industry rank of 94 out of 265 based on the ratings given to its competitors.
Several brokerages have recently commented on XTNT. Zacks Investment Research lowered Xtant Medical Holdings from a “hold” rating to a “sell” rating in a report on Wednesday, June 8th. HC Wainwright reissued a “buy” rating on shares of Xtant Medical Holdings in a report on Thursday, August 4th.
Xtant Medical Holdings (NASDAQ:XTNT) traded down 3.3391% on Wednesday, reaching $1.1116. 5,593 shares of the company’s stock traded hands. The firm’s market cap is $13.55 million. The firm’s 50-day moving average is $1.35 and its 200 day moving average is $1.95. Xtant Medical Holdings has a 12 month low of $0.93 and a 12 month high of $3.75.
Xtant Medical Holdings Company Profile
Xtant Medical Holdings, Inc, formerly Bacterin International Holdings, Inc, develops, manufactures and markets regenerative medicine products and medical devices for domestic and international markets. The Company operates through the development, manufacture and marketing of regenerative medical products and devices segment.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Xtant Medical Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xtant Medical Holdings Inc and related companies with MarketBeat.com's FREE daily email newsletter.